These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

708 related articles for article (PubMed ID: 27906680)

  • 1. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
    Qiu X; Ma J; Wang K; Zhang H
    Oncotarget; 2017 Jan; 8(1):1031-1045. PubMed ID: 27906680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
    Terdiman JP; Steinbuch M; Blumentals WA; Ullman TA; Rubin DT
    Inflamm Bowel Dis; 2007 Apr; 13(4):367-71. PubMed ID: 17206695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Aminosalicylic acid and chemoprevention: does it work?
    Lopez A; Peyrin-Biroulet L
    Dig Dis; 2013; 31(2):248-53. PubMed ID: 24030235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study.
    Mak JWY; So J; Tang W; Yip TCF; Leung WK; Li M; Lo FH; Ng KM; Sze SF; Leung CM; Tsang SWC; Shan EHS; Chan KH; Lam BCY; Hui AJ; Chow WH; Chan FKL; Ng SC
    Scand J Gastroenterol; 2020 Mar; 55(3):279-286. PubMed ID: 32119788
    [No Abstract]   [Full Text] [Related]  

  • 5. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
    Bernstein CN; Nugent Z; Blanchard JF
    Am J Gastroenterol; 2011 Apr; 106(4):731-6. PubMed ID: 21407180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients' knowledge and fear of colorectal cancer risk in inflammatory bowel disease.
    Lopez A; Collet-Fenetrier B; Belle A; Peyrin-Biroulet L
    J Dig Dis; 2016 Jun; 17(6):383-91. PubMed ID: 27129893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review with meta-analysis: thiopurines decrease the risk of colorectal neoplasia in patients with inflammatory bowel disease.
    Lu MJ; Qiu XY; Mao XQ; Li XT; Zhang HJ
    Aliment Pharmacol Ther; 2018 Feb; 47(3):318-331. PubMed ID: 29205426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease.
    van Schaik FD; van Oijen MG; Smeets HM; van der Heijden GJ; Siersema PD; Oldenburg B
    Gut; 2012 Feb; 61(2):235-40. PubMed ID: 21602529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesalamine protects against colorectal cancer in inflammatory bowel disease.
    Tang J; Sharif O; Pai C; Silverman AL
    Dig Dis Sci; 2010 Jun; 55(6):1696-703. PubMed ID: 19705280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study.
    van Staa TP; Card T; Logan RF; Leufkens HG
    Gut; 2005 Nov; 54(11):1573-8. PubMed ID: 15994215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.
    Mahmud N; Weir DG; Kelleher D
    Ir J Med Sci; 1999; 168(4):228-32. PubMed ID: 10624358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Aminosalicylic Acid Chemoprevention in Inflammatory Bowel Diseases: Is It Necessary in the Age of Biologics and Small Molecules?
    Herfarth H; Vavricka SR
    Inflamm Intest Dis; 2022 Jan; 7(1):28-35. PubMed ID: 35224015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease.
    Chan EP; Lichtenstein GR
    Gastroenterol Clin North Am; 2006 Sep; 35(3):675-712. PubMed ID: 16952746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.
    Velayos FS; Terdiman JP; Walsh JM
    Am J Gastroenterol; 2005 Jun; 100(6):1345-53. PubMed ID: 15929768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease.
    Cheng Y; Desreumaux P
    World J Gastroenterol; 2005 Jan; 11(3):309-14. PubMed ID: 15637733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update.
    Rubin DT; Cruz-Correa MR; Gasche C; Jass JR; Lichtenstein GR; Montgomery EA; Riddell RH; Rutter MD; Ullman TA; Velayos FS; Itzkowitz S;
    Inflamm Bowel Dis; 2008 Feb; 14(2):265-74. PubMed ID: 17932965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
    Klotz U
    Arzneimittelforschung; 2012 Feb; 62(2):53-8. PubMed ID: 22344548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations.
    Nguyen GC; Gulamhusein A; Bernstein CN
    Am J Gastroenterol; 2012 Sep; 107(9):1298-304; quiz 1297, 1305. PubMed ID: 22751467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease.
    Bonovas S; Fiorino G; Lytras T; Nikolopoulos G; Peyrin-Biroulet L; Danese S
    Aliment Pharmacol Ther; 2017 May; 45(9):1179-1192. PubMed ID: 28261835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprevention of colorectal cancer in ulcerative colitis.
    Croog VJ; Ullman TA; Itzkowitz SH
    Int J Colorectal Dis; 2003 Sep; 18(5):392-400. PubMed ID: 12904996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.